Last reviewed · How we verify
Prevention of Transient Ischemic Attacks
Approved treatments
- Zocor · Merck & Co.
- Crestor · AstraZeneca
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Transient Ischemic Attacks patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Transient Ischemic Attacks treatment landscape brief
- Prevention of Transient Ischemic Attacks treatment updates RSS
Frequently asked questions about Prevention of Transient Ischemic Attacks
What drugs treat Prevention of Transient Ischemic Attacks?
Tracked treatments include Zocor, Crestor.
What is the treatment for Prevention of Transient Ischemic Attacks?
Standard treatment for Prevention of Transient Ischemic Attacks includes Zocor, Crestor. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Transient Ischemic Attacks patent cliff · Prevention of Transient Ischemic Attacks CI report
- Treatment: Zocor · Merck & Co.
- Treatment: Crestor · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing